This module uses fundamental data of Clearmind Medicine to approximate its Piotroski F score. Clearmind Medicine F Score is determined by combining nine binary scores representing 3 distinct fundamental categories of Clearmind Medicine Common. These three categories are profitability, efficiency, and funding. Some research analysts and sophisticated value traders use Piotroski F Score to find opportunities outside of the conventional market and financial statement analysis.They believe that some of the new information about Clearmind Medicine financial position does not get reflected in the current market share price suggesting a possibility of arbitrage. Check out Clearmind Medicine Altman Z Score, Clearmind Medicine Correlation, Clearmind Medicine Valuation, as well as analyze Clearmind Medicine Alpha and Beta and Clearmind Medicine Hype Analysis.
Clearmind
Piotroski F Score
Market Cap
Enterprise Value
Ptb Ratio
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Average Payables
Capex To Depreciation
Pb Ratio
Free Cash Flow Per Share
Roic
Net Income Per Share
Cash Per Share
Pocfratio
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Intangibles To Total Assets
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Graham Number
Shareholders Equity Per Share
Capex Per Share
Graham Net Net
Enterprise Value Over E B I T D A
Price Earnings Ratio
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Ebt Per Ebit
Effective Tax Rate
Company Equity Multiplier
Return On Capital Employed
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Cash Ratio
Cash Conversion Cycle
Free Cash Flow Operating Cash Flow Ratio
Price To Book Ratio
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Return On Assets
Price Fair Value
Return On Equity
Change In Cash
Net Borrowings
Other Cashflows From Financing Activities
Capital Expenditures
Total Cash From Operating Activities
Change To Operating Activities
Net Income
Total Cash From Financing Activities
Change To Liabilities
End Period Cash Flow
Stock Based Compensation
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Total Cashflows From Investing Activities
Depreciation
Other Non Cash Items
Change To Account Receivables
Other Cashflows From Investing Activities
Change To Netincome
Change To Inventory
Investments
Issuance Of Capital Stock
Total Assets
Total Current Liabilities
Total Stockholder Equity
Net Tangible Assets
Retained Earnings
Accounts Payable
Cash
Other Current Assets
Total Liab
Short Long Term Debt
Total Current Assets
Short Term Debt
Common Stock
Other Current Liab
Property Plant And Equipment Net
Net Debt
Non Current Assets Total
Cash And Short Term Investments
Net Receivables
Liabilities And Stockholders Equity
Non Current Liabilities Total
Common Stock Shares Outstanding
Other Stockholder Equity
Property Plant Equipment
Net Invested Capital
Accumulated Other Comprehensive Income
Capital Stock
Net Working Capital
Property Plant And Equipment Gross
Non Currrent Assets Other
Other Assets
Short Term Investments
Intangible Assets
Interest Expense
Selling General Administrative
Gross Profit
Operating Income
Net Income From Continuing Ops
Ebit
Cost Of Revenue
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Net Income Applicable To Common Shares
Income Tax Expense
Other Operating Expenses
Ebitda
Tax Provision
Net Interest Income
Depreciation And Amortization
Research Development
Reconciled Depreciation
Probability Of Bankruptcy
As of January 23, 2025, Short and Long Term Debt is expected to decline to about 24.9 K. In addition to that, Short Term Debt is expected to decline to about 26.4 K. At present, Clearmind Medicine's Average Payables is projected to increase significantly based on the last few years of reporting. The current year's PB Ratio is expected to grow to 0.51, whereas Free Cash Flow Yield is forecasted to decline to (7.44).
At this time, it appears that Clearmind Medicine's Piotroski F Score is Unavailable. Although some professional money managers and academia have recently criticized Piotroski F-Score model, we still consider it an effective method of predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
The critical factor to consider when applying the Piotroski F Score to Clearmind Medicine is to make sure Clearmind is not a subject of accounting manipulations and runs a healthy internal audit department. So, if Clearmind Medicine's auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if Clearmind Medicine's financial numbers are properly reported.
One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to project the various growth rates. Understanding the correlation between Clearmind Medicine's different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Clearmind Medicine in a much-optimized way.
F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.
Book Value Per Share
3.02
At present, Clearmind Medicine's Book Value Per Share is projected to increase based on the last few years of reporting.
Clearmind Medicine Current Valuation Drivers
We derive many important indicators used in calculating different scores of Clearmind Medicine from analyzing Clearmind Medicine's financial statements. These drivers represent accounts that assess Clearmind Medicine's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Clearmind Medicine's important valuation drivers and their relationship over time.
The Macroaxis Fundamental Analysis modules help investors analyze Clearmind Medicine Common's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Clearmind Medicine using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Clearmind Medicine Common based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Clearmind Medicine Common is a strong investment it is important to analyze Clearmind Medicine's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Clearmind Medicine's future performance. For an informed investment choice regarding Clearmind Stock, refer to the following important reports:
You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Clearmind Medicine. If investors know Clearmind will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Clearmind Medicine listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.23)
Return On Assets
(0.58)
Return On Equity
(2.68)
The market value of Clearmind Medicine Common is measured differently than its book value, which is the value of Clearmind that is recorded on the company's balance sheet. Investors also form their own opinion of Clearmind Medicine's value that differs from its market value or its book value, called intrinsic value, which is Clearmind Medicine's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Clearmind Medicine's market value can be influenced by many factors that don't directly affect Clearmind Medicine's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Clearmind Medicine's value and its price as these two are different measures arrived at by different means. Investors typically determine if Clearmind Medicine is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Clearmind Medicine's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.